Neutrophil Activation: Influence of Antimony Tolerant and Susceptible Clinical Strains of and Meglumine Antimoniate.

Front Cell Infect Microbiol

Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Cali, Colombia.

Published: October 2021

AI Article Synopsis

  • Recent research shows that the body's natural immune response may play a role in how well antimicrobial drugs work, particularly against leishmaniasis.
  • The study focused on how clinical strains of parasites resistant to a common antileishmanial drug, pentavalent antimony (SbV), affect neutrophil activation by comparing sensitive and resistant strains.
  • The findings indicate that neutrophils infected with drug-resistant strains produce less reactive oxygen species and have a different expression profile for specific activation markers compared to those infected with drug-sensitive strains.

Article Abstract

Emerging evidence indicates that innate host response contributes to the therapeutic effect of antimicrobial medications. Recent studies have shown that parasites derived by selection for resistance to pentavalent antimony (SbV) as meglumine antimoniate (MA) modulate the activation of neutrophils. However, whether modulation of neutrophil activation extends to natural resistance to this antileishmanial drug has not been established. We have evaluated the influence of clinical strains of having intrinsic tolerance/resistance to SbV, on the inflammatory response of neutrophils during exposure to MA. Accordingly, neutrophils obtained from healthy donors were infected with clinical strains that are sensitive (n = 10) or intrinsically tolerant/resistant to SbV (n = 10) and exposed to a concentration approximating the maximal plasma concentration (Cmax) of SbV (32 µg/ml). The activation profile of neutrophils was evaluated as the expression of the surface membrane markers CD66b, CD18, and CD62L by flow cytometry, measurement of reactive oxygen species (ROS) by luminometry, and NET formation using Picogreen to measure dsDNA release and quantification of NETs by confocal microscopy. These parameters of activation were analyzed in relation with parasite susceptibility to SbV and exposure to MA. Here, we show that clinical strains presenting intrinsic tolerance/resistance to SbV induced significantly lower ROS production compared to drug-sensitive clinical strains, both in the presence and in the absence of MA. Likewise, analyses of surface membrane activation markers revealed significantly higher expression of CD62L on cells infected with intrinsically SbV tolerant/resistant than cells infected with drug-sensitive strains. Expression of other activation markers (CD18 and CD66b) and NET formation were similar for neutrophils infected with SbV sensitive and tolerant clinical strains under the conditions evaluated. Exposure to MA broadly impacted the activation of neutrophils, diminishing NET formation and the expression of CD62L, while augmenting ROS production and CD66b expression, independently of the parasite susceptibility phenotype. These results demonstrated that activation of human neutrophils is differentially modulated by infection with clinical strains of having intrinsic tolerance/resistance to SbV compared to sensitive strains, and by exposure to antimonial drug.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493214PMC
http://dx.doi.org/10.3389/fcimb.2021.710006DOI Listing

Publication Analysis

Top Keywords

clinical strains
28
intrinsic tolerance/resistance
12
tolerance/resistance sbv
12
net formation
12
strains
9
sbv
9
neutrophil activation
8
meglumine antimoniate
8
activation
8
activation neutrophils
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!